Top Industry Leaders in the Hip Tendinitis Market
Latest Hip Tendinitis Companies Update
Zimmer Biomet Launched the Q-Fix Anterior Hip System, designed for enhanced stability and fixation in Direct Anterior Approach (DAA) hip replacement procedures. This minimally invasive approach is gaining popularity due to its faster recovery times and smaller incisions.
Smith+Nephew Received FDA clearance for its POLAROSQ™ Stemless Shoulder System, expanding its DAA portfolio beyond hip replacements. This system offers surgeons greater flexibility and potential for improved patient outcomes.
Stryker Invested in OSSIG, a developer of software for personalized surgical planning in joint replacements, including DAA procedures. This technology helps surgeons create patient specific implant plans for a more precise and efficient surgery.
OrthAlign, Collaborated with The Centers for Advanced Orthopaedics to implement its NAVIO® Surgical System for robotic-assisted DAA hip replacements. This system utilizes robotic arms to guide surgeons during the procedure, potentially improving accuracy and reducing complications.
Proliance Surgeons Partnered with hospitals and clinics across the U.S. to expand access to DAA surgeries and improve patient outcomes. This initiative aims to make this minimally invasive option more readily available to patients suffering from hip tendinitis.
List of Hip Tendinitis Key companies in the market
- Almatica Pharma, Inc (U.S.)
- AstraZeneca (U.K.)
- Bayer AG (Germany)
- Boehringer Ingelheim Pharmaceuticals, Inc (Germany)
- Merck & Co., Inc (U.S.)
- Pfizer (U.S.)
- Abbott (U.S.)
- GlaxoSmithKline plc (U.K.)
- Teva Pharmaceuticals (Taiwan)
- Lupin Pharmaceuticals, Inc. (India)
- Geri-Care Pharmaceuticals. (U.S.)
- Perrigo Company (U.S)